INTANGIBLE ASSETS AND GOODWILL (Tables)

3 Months Ended

Mar. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of net-book value and estimated remaining life and finite lived intangible assets

The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of March 31, 2020:​

(In thousands)	Weighted Average Remaining Life (Years)	Cost		Accumulated Amortization		Net Balance at March 31, 2020
Finite-lived intangible assets
Trade name	15.7	$	100,700	$	(2,535)	$	98,165
Customer relationships	13.6	2,700		(269)		2,431
Patents	8.6	22,689		(6,539)		16,150
Acquired developed technology	9.7	814,171		(32,510)		781,661
Supply agreements	7.3	30,000		(1,560)		28,440
Internally developed technology	2.4	1,508		(449)		1,059
Total finite-lived intangible assets		971,768		(43,862)		927,906
In-process research and development	n/a	200,000		—		200,000
Internally developed technology in process	n/a	355		—		355
Total intangible assets		$	1,172,123	$	(43,862)	$	1,128,261

The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of December 31, 2019:​

(In thousands)	Weighted Average Remaining Life (Years)	Cost		Accumulated Amortization		Net Balance at December 31, 2019
Finite-lived intangible assets
Trade name	15.9	$	100,700	$	(961)	$	99,739
Customer relationships	13.6	2,700		(224)		2,476
Patents	8.8	22,690		(5,974)		16,716
Acquired developed technology	9.9	806,371		(12,345)		794,026
Supply agreements	7.5	30,000		(571)		29,429
Internally developed technology	2.5	1,229		(336)		893
Total finite-lived intangible assets		963,690		(20,411)		943,279
In-process research and development	n/a	200,000		—		200,000
Internally developed technology in process	n/a	271		—		271
Total intangible assets		$	1,163,961	$	(20,411)	$	1,143,550

Schedule of estimated future amortization expense, intangible assets

As of March 31, 2020, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows:​

(In thousands)
2020	$	70,667
2021	94,121
2022	93,915
2023	93,692
2024	93,345
Thereafter	482,166
​	$	927,906

Schedule of Carrying Amount of Goodwill

The change in the carrying amount of goodwill for the periods ended March 31, 2020 and December 31, 2019 is as follows:

(In thousands)
Balance, January 1, 2019	$	17,279
Genomic Health acquisition	1,185,918
Balance, December 31, 2019	1,203,197
Paradigm & Viomics acquisition	29,695
Genomic Health acquisition adjustment	4,269
Balance, March 31, 2020	$	1,237,161